◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Invesco Nasdaq Biotechnology ETF (IBBQ) ETF Overview

Name: Invesco Nasdaq Biotechnology ETF (IBBQ) price history and fund statistics
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Price history, fund statistics and profile — an exchange-traded fund.

Exchange-Traded Funds · Health · DATA UPDATED 2026-08-31

Invesco Nasdaq Biotechnology ETF (IBBQ) is an exchange-traded fund managed by Invesco in the "Health" category. It manages roughly $76 million in assets.

The fund generally will invest at least 90% of its total assets in the securities that comprise the index.

Interactive chart & fund stats →

IBBQ Fund Statistics

Expense ratio	0.19%
Trailing yield	0.80%
Assets under management	$76 million
Fund category	Health
Fund family	Invesco
Inception	2021-06-11

The live price chart, fund profile and news are in the interactive IBBQ viewer.

Other Companies in Health

BBP · Virtus LifeSci Biotech Products ETF — $99 million
AGNG · Global X Aging Population ETF — $87 million
GNOM · Global X Genomics & Biotechnology ETF — $80 million
SURI · Simplify Propel Opportunities ETF — $78 million
HTEC · Robo Global Healthcare Technology and Innovation ETF — $69 million
OZEM · Roundhill Glp-1 & Weight Loss ETF — $61 million
HRTS · Tema Heart & Health ETF — $54 million
BBC · Virtus LifeSci Biotech Clinical Trials ETF — $46 million

← IBB All “I” companies IBCA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.